Anavex Posts $131.7M Cash, Cuts R&D to $4.7M, Advances Alzheimer’s Drug
Anavex ended FY2026 Q1 with $131.7M cash, up from $102.6M, providing more than three years’ runway while cutting R&D spend to $4.7M from $10.4M. The company advanced oral blarcamesine in early Alzheimer’s with FDA Type C feedback on NDA pathways and requested EMA re-examination after a negative CHMP opinion.
1. Financial Results
At December 31, 2025, Anavex held $131.7 million in cash and equivalents, up from $102.6 million at September 30, 2025, supporting over three years of operating runway at current burn rates. Research and development expenses declined to $4.7 million for the quarter, compared to $10.4 million in the year-ago period.
2. Regulatory Updates
During a Type C meeting with the FDA, the agency expressed interest in Anavex’s NDA pathway for oral blarcamesine in early Alzheimer’s disease and requested submission of existing Phase IIb/III data. The EMA’s CHMP delivered a negative opinion on the marketing authorization application but agreed to re-examine the filing under new rapporteurs.
3. Clinical Pipeline Progress
Anavex continues to advance its lead candidate, oral blarcamesine, through regulatory pathways and clinical trials in early Alzheimer’s, Parkinson’s disease and Rett syndrome. The company is designing a Phase 2/3 trial for Fragile X syndrome, progressing ANAVEX®3-71 toward pivotal schizophrenia studies, and preparing presentations on biomarker correlations and precision medicine findings at upcoming conferences.
4. Corporate Milestones
Anavex joined the ACCESS-AD European initiative to accelerate innovative Alzheimer’s diagnostics and therapies in real-world settings. The company also appointed Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology, and will present new scientific findings at the ICFSR26 conference in March 2026.